Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Alterity PBT434 Poster Presented at 2019 MDS Congress

October 3, 2019August 16, 2022 Alterity Therapeutics

Alterity PBT434 Poster – MDS 2019 Congress

2019

Post navigation

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Quarterly Cash Flow Report

Related Posts

Prana Completes Phase 2 Huntington Disease Trial with PBT2

October 6, 2013August 16, 2022

Life Biosciences LLC leads strategic investment of up to A$44.5 million in Prana

December 27, 2018August 16, 2022

Prana Biotechnology 2014 Annual Report

October 1, 2014August 16, 2022

Recent Posts

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
XBRL 30 June 2022 filed with the SEC
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065